Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO |
| |
Authors: | Pivot Xavier Schneeweiss Andreas Verma Shailendra Thomssen Christoph Passos-Coelho José Luis Benedetti Giovanni Ciruelos Eva von Moos Roger Chang Hong-Tai Duenne Anja-Alexandra Miles David W |
| |
Institution: | aUniversity Hospital of Besançon, Besançon, France;bNational Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany;cThe Ottawa Hospital Cancer Centre, Ottawa, ON, Canada;dFrauenklinik Universitaet Halle-Wittenberg, Halle, Germany;eInstituto Português de Oncologia, Lisbon, Portugal;fOncology Hospital of Macerata, Macerata, Italy;gHospital Universitario 12 de Octubre, Madrid, Spain;hMedical Oncology Kantonsspital Graubuenden, Chur, Switzerland;iKaohsiung Veterans General Hospital, Kaohsiung, Taiwan;jF. Hoffmann-La Roche Ltd., Pharmaceutical Division, Basel, Switzerland;kMount Vernon Cancer Centre, Middlesex, United Kingdom |
| |
Abstract: | BackgroundOncologic treatment in elderly patients is challenging, due to comorbidities, often impaired organ function, limited clinical trial evidence, inadequate guidelines and no consistent ‘elderly’ definition. We report exploratory sub-analyses of safety and efficacy in elderly patients, defined as ?65 years old, in AVastin And DOcetaxel (AVADO) receiving first-line bevacizumab plus docetaxel for metastatic breast cancer (mBC).Patients and methodsPatients with HER2-negative, locally recurrent or mBC were randomised to 3-weekly docetaxel (100 mg/m2) with placebo, bevacizumab 7.5 mg/kg or bevacizumab 15 mg/kg, for 9 cycles or until disease progression or unacceptable toxicity. Patients had no prior chemotherapy for mBC.ResultsProgression-free survival (PFS) was increased with bevacizumab in the elderly subpopulation (n = 127), the effect being greater with higher dose (hazard ratio = 0.63 95% confidence interval (CI) 0.383–1.032] versus 0.76 95% CI: 0.46–1.262], respectively). PFS was numerically similar in the elderly and overall populations, but the former failed to achieve statistical significance. Overall response rates for docetaxel plus placebo, bevacizumab 7.5 mg/kg and 15 mg/kg were 44.7%, 36.6% and 50.0%, respectively. Effects on survival were not statistically significant. Bevacizumab was well tolerated in elderly patients, the most common adverse effects were neutropenia and febrile neutropenia; there was no excess of grade ? 3 cardiovascular events. There was no clear correlation between baseline hypertension and its development during study treatment.ConclusionsIn this exploratory sub-analysis in AVADO, bevacizumab plus docetaxel showed efficacy in elderly patients similar to the overall study population. There were no unexpected safety signals in patients aged 65 years or older. |
| |
Keywords: | Bevacizumab Elderly Taxane Docetaxel Metastatic breast cancer |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|